Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Ovarian Neoplasms 1Myelodysplastic Syndromes 1Leukemia 1Inflammatory Breast Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 22Paclitaxel 12Epirubicin 12Doxorubicin 11Trastuzumab 10Docetaxel 10Carboplatin 10Taxes 7Bevacizumab 6pembrolizumab 5Radiotherapy 5Filgrastim 5Albumin-Bound Paclitaxel 5Neoadjuvant Therapy 4130-nm albumin-bound paclitaxel 4Thiotepa 3Tamoxifen 3Panitumumab 3Melphalan 3Lapatinib 3Granulocyte Colony-Stimulating Factor 3Fluorouracil 3Chemotherapy, Adjuvant 3sargramostim 2pertuzumab 2eribulin 2Radiation 2Peripheral Blood Stem Cell Transplantation 2Cisplatin 2Capecitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Inflammatory Breast Neoplasms × NOV 002 × Clear all
NCT00499122 2018-01-02

NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer

University of Miami

Phase 2 Completed
41 enrolled 10 charts
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡